

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/159154 A1

(51) International Patent Classification:

A61P 29/00 (2006.01) *C07D 471/04* (2006.01)
A61P 35/00 (2006.01) *C07D 519/00* (2006.01)
A61P 37/00 (2006.01) *A61K 31/437* (2006.01)

(21) International Application Number:

PCT/US2023/062780

(22) International Filing Date:

17 February 2023 (17.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/311,612 18 February 2022 (18.02.2022) US
63/379,340 13 October 2022 (13.10.2022) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **YOON, David S.**; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US). **LIU, Chunjian**; c/o Bristol-My-
ers Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **REGUEIRO-REN,**
Alicia; c/o Bristol-Myers Squibb Company, Route 206 and
Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: **GREENBLATT, Gary D.** et al.; Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9



(57) Abstract: Disclosed are compounds of Formulas (I): (Formulas (I)) or a salt thereof, wherein X, Y, Q, G, R₁, and R_{5a} are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing fibrotic diseases.

WO 2023/159154 A1